Dianthus Therapeutics (NASDAQ:DNTH) Upgraded to “Moderate Buy” at Raymond James

Dianthus Therapeutics (NASDAQ:DNTH) was upgraded by stock analysts at Raymond James to a “moderate buy” rating in a report released on Thursday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $23.81 on Thursday. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The business has a fifty day moving average price of $26.09 and a 200-day moving average price of $26.54. The firm has a market capitalization of $704.78 million, a price-to-earnings ratio of -9.52 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. On average, equities research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Dianthus Therapeutics by 860.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after purchasing an additional 72,509 shares during the last quarter. HighVista Strategies LLC purchased a new stake in shares of Dianthus Therapeutics in the third quarter worth about $542,000. SG Americas Securities LLC boosted its stake in Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after buying an additional 4,506 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Dianthus Therapeutics by 151.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after buying an additional 263,500 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. increased its stake in Dianthus Therapeutics by 281.9% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock worth $1,022,000 after acquiring an additional 29,159 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.